The United States Food and Drug Administration (FDA) officials stated in a report that Moderna Inc.'s COVID-19 vaccine is safe for children aged from 6 months to 17 years. The study, which included around 11,000 recipients, found adverse effects were "mostly mild to moderate," generally of short duration, and more likely to occur after the second dose.
Meanwhile, the efficacy of the vaccine was reported at 93.3% in children aged 12-17, although it dropped to 36.8% and 50.6% respectively for children between 2 and 5 years of age and 6 to 23 months of age who were evaluated when the Omicron variant was predominant.
